Introduction
It is generally accepted that hypertension increases stiffness of the large arteries by inducing several changes in levels of local hormonal factors, leading to structural alterations of the arterial wall. Clinical and epidemiological studies have shown that subjects with stiffer arteries have a greater pulse pressure and that stiffening of large arteries is associated with cardiac hypertrophy and excess morbidity and mortality independently of other cardiovascular risk factors [1] [2] [3] [4] . Therefore, identification of the molecular determinants regulating arterial stiffness is of major interest. We have recently shown that the angiotensin II type 1 receptor gene polymorphism was a significant determinant of development of arterial stiffness in hypertensives [5, 6] and of its regression with the antihypertensive treatment [7] . In contrast, angiotensin converting enzyme insertion/deletion polymorphism did not play a major role in determination of arterial stiffness [5] . Because other studies have also shown that there are significant associations of genetic polymorphisms with several cardiovascular phenotypes, including left ventricular [8] and carotid artery hypertrophy [9] and cardiovascular mortality [10, 11] , it is important to determine whether other candidate genes are involved in determining arterial stiffness.
Because of the important effect of NO on blood pressure and the reduced basal release of endothelial NO in hypertension [12] [13] [14] , the gene of endothelial nitric oxide synthase (ENOS), which has been shown to be poly- Objective To assess the contribution of two polymorphisms of the endothelial nitric oxide synthase gene to aortic stiffness in normotensive and hypertensive subjects in the same cohort.
Methods We studied 309 untreated hypertensive and 123 normotensive subjects. Aortic stiffness was evaluated by measuring the carotid-femoral pulse-wave velocity non-invasively. The endothelial nitric oxide synthase gene polymorphisms G 10 -T at intron 23 (G IN23 T) and G 298 -T at exon 7 (Glu 298 Asp) were determined in each subject.
Results
The distributions of genotypes and allele prevalences of the endothelial nitric-oxide synthase G 10 -T polymorphisms among hypertensive and normotensive subjects were similar. In contrast, the prevalence of the nitric oxide synthase 298 G allele was higher in the hypertensive group than it was among normotensive subjects. We found no association of the endothelial nitric oxide synthase genotypes with blood pressure levels or pulse-wave velocity for either population. morphic [15] , is a putative candidate gene for hypertension. Two recent studies revealed no linkage between hypertension and the ENOS gene [16, 17] . However, these studies were focused on blood pressure and they did not concern a possible involvement of the ENOS gene in hypertension-induced alterations of arterial parameters. In the present study we evaluated the association of arterial stiffness with two recently described polymorphisms of the ENOS gene; namely G 10 T polymorphism located in intron 23 (G IN23 T) [16] and G
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T polymorphism located in exon 7 (Glu 298 Asp) [18] . No significant association of the G
IN23
T with arterial hypertension has been found [16] . To the best of our knowledge, the exon 7 polymorphism in hypertensive patients has not been studied. Because this polymorphism modifies the coding sequence of the ENOS gene, resulting in a change in amino acid (Glu 298 Asp), it could be of some interest to evaluate the role of the ENOS gene in hypertension-induced alterations of arterial parameters.
The aim of the present study was to determine the association of the ENOS G IN23 T and Glu 298 Asp polymorphisms with aortic stiffness assessed by carotid-femoral pulse-wave velocity (PWV) measurements in hypertensive and in normotensive subjects [19, 20] . We found that the Glu 298 allele prevalence was greater among hypertensives than it was among normotensives. However, neither ENOS G
T nor Glu 298 Asp polymorphism was associated with PWV.
Methods
We studied 311 hypertensive patients of European ancestry aged 18-74 years and 128 normotensive subjects aged 19-72 years. This cohort was the same as that which we have previously described [5] .
Normotensives were selected according to fulfilment of the following criteria: no history of hypertension and coronary artery disease; systolic blood pressure (SBP) on the morning of the study < 140 mmHg and diastolic blood pressure (DBP) < 90 mmHg, measured both with a sphygmomanometer and with a Dinamap 845 device (Dinamap, Tampa, Florida, USA); and no recent symptoms of coronary artery disease, heart failure, stroke incidence and lower limb arterial disease.
Hypertensives were selected according to fulfilment of the following criteria: a history of hypertension; no administration of antihypertensive or vasodilator treatments, for at least 3 weeks before the day of the study; SBP on the morning of the study > 140 mmHg or DBP > 90 mmHg, measured both with a sphygmomanometer (mean of three measurements with the subject supine, Korotkoff phase V) and with an automatic oscillometric device (Dinamap); no clinical or biological signs of secondary hypertension; and no recent symptoms of coronary artery disease, heart failure, stroke incidence and lower limb arterial disease.
All the participants were examined in the morning after they had fasted for at least 12 h and all were subjected to the same procedure after they had provided their written informed consent to participate in our study. After 15 min supine rest, carotid-femoral PWV was evaluated using two pressure probes. This method has been described extensively previously [5, 20] . Briefly, two pressure waves were recorded transcutaneously at two sites (at the base of the neck for the common carotid artery and over the right femoral artery). PWV was determined as the foot-to-foot velocity. The foot of the pressure wave was identified as the point of the beginning of the sharp systolic up-stroke. Pulse transit time was determined as the average of 10 consecutive beats and the mean value of two different observers' readings was retained for the statistical analysis. The distance travelled by the pulse wave was measured over the body surface as the distance between the two recording sites. Aortic PWV was calculated as the distance : transit time ratio. The reproducibility of the measurement for aortic PWV (expressed as percentage variation of the mean value) has been found to be 5.3 ± 3.6% [20] .
During the procedure and for 5 min afterwards, blood pressure was measured automatically every 2 min with a Dinamap device. The mean of five consecutive measurements was calculated. An automatic method was chosen for the statistical analysis in order to avoid inter-observer variations and diminish the 'white-coat' reactivity. At the end of this procedure, plasma was drawn for determination of standard biochemical measurements and DNA extraction.
Genotype investigation
Blood was drawn for DNA extraction. Genotyping of all subjects was performed using allele-specific oligonucleotides as previously described [15, 16] . The primers used for polymerase chain reaction amplification of G 10 T of intron 23 were as follows: upper, 5′ATT GCC CCC TTC CGG GGA TTC T3′ and lower, 5′AGC CCC ACC CCT CTG TCC CTA G3′; and for the G 298 T polymorphism: upper, 5′CCCC ACA GCT CTG CAT TCA G3′ and lower, 5′TCC ATC CCA CCC AGT CAA TC 3′. After enzymatic amplification a fifth of the polymerase chain reaction product was denaturated and blotted onto nylon membranes. Each allele was detected after incubation with specific oligonucleotide probes [for G 10 5′TTT AGT CCC CAG CCT3′ (reverse strand) and for T 10 5′AGG CTG GTG ACT AAA3′; the temperatures of hybridation were 41 and 39°C, respectively; for G 298 5′ CCA GAT GAG CCC CCA GA 3′ and for T 298 5′CCA GAT GAT CCC CCA GA 3′ with hybridization temper-
Statistical analysis
The statistical analysis was performed only for data sets without any missing values (i.e. for data from 309 hypertensives and 123 normotensives). Both polymorphisms were tested as three classes of variables or as codominant 0, 1 and 2 ordinal variables (absence and presence of one or two T alleles, respectively). Interaction tests were performed to assess the homogeneity of genotype-phenotype association for normotensive and hypertensive subjects. Multiple regression analyses were performed separately for data from normotensive and hypertensive subjects to evaluate the effects of the genetic polymorphisms on PWV after adjustment for covariables. Hardy-Weinberg equilibrium and allele prevalences in the two populations were tested by using a 2 test.
Results
The 7), the prevalence of the G allele was higher in the hypertensive group than it was among normotensive subjects ( 2 = 10.88, P = 0.004).
The main characteristics of the hypertensive and normotensive subjects according to ENOS genotypes are shown in Tables 2 (G   IN23   T) T (exon 7), the higher incidence of the G allele in hypertensive group was significant ( 2 = 10.88, P = 0.004). Values are expressed as means ± SEM. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; PWV, pulse-wave velocity. For both groups, all comparisons according to the genotype were not significant. Values are expressed as means ± SEM. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; PWV, pulse-wave velocity. For both groups, all comparisons according to the genotype were not significant.
and age were similar across genotypes of the two studied polymorphisms both for normotensive and for hypertensive subjects. Multiple regression analysis testing the contributions of age, SBP and genotypes to PWV detected no association of the genotypes with aortic stiffness both for normotensive and for hypertensive individuals (Table 4) .
Discussion
Two previous studies provided no evidence that molecular variants of the ENOS gene are involved in hypertension. In the present study, we tested the associations of aortic stiffness with two polymorphisms of the ENOS gene. The results suggest that G
IN23 T (intron 23) and Glu 298
Asp (exon 7) polymorphisms are not involved in the regulation of aortic stiffness both for hypertensive and for normotensive individuals.
To perform this study we determined ENOS genotypes in members of a cohort of normotensive and hypertensive subjects that we have previously analysed and among whom we had demonstrated that there is a significant association of the angiotensin II type 1 A 1166 C receptor polymorphism with aortic stiffness [5] . Aortic stiffness in hypertensive and normotensive subjects was assessed by measuring carotid-femoral PWV [5, 19, 20] . A high PWV indicates a high volumic arterial stiffness [1] . Results of clinical and epidemiological studies strongly indicate that subjects with stiffer arteries have large pulse pressures, and that stiffening of large arteries is associated with cardiac hypertrophy and excess morbidity independently of other cardiovascular risk factors [1] [2] [3] .
The role of NO at the level of large arteries in humans has recently been clarified by using specific inhibitors of nitric oxide synthase (NOS). Joannides et al. [21] showed that NOS inhibitors decreased radial artery diameter in normotensive humans, without affecting mean blood pressure level, indicating that basal release of NO is important for maintaining a tonic vasodilating action. However, the relationship between large artery dilatation and mechanical properties is complex. After vasodilatation, arterial stiffness can be increased or decreased according to the degree of relaxation of the vascular smooth muscle cells [22] . An increase in diameter in the absence of vascular relaxation, such as those observed during ageing and in hypertension, leads to a decrease in arterial distensibility. The opposite is observed when vasodilatation is accompanied by vasorelaxation [22] . NO could also influence arterial mechanical properties via regulating proliferation of smooth muscle cells. Indeed, Garg and Hassid [23] showed that the NO-cyclic GMP cascade inhibits mitogenesis and proliferation of rat vascular smooth muscle cells in vitro.
Results of several studies concerning human and experimental hypertension have shown that production of NO is decreased and that the NO-dependent dilatation is blunted [24] [25] [26] . The main factor for the impairment of the NO-cyclic GMP pathway in hypertension seems to be located at the level of the ENOS. Huang et al. [27] showed that disruption of the gene encoding NOS in mice is associated with development of hypertension.
The present results confirm recently published data revealing the lack of an association of the ENOS G IN23 T polymorphism with blood pressure level or incidence of hypertension [16] . Our study was not designed to assess the role of the ENOS polymorphisms in regulation of blood pressure. It remains, however, an interesting observation that the prevalence of the NOS 298 G allele was higher in the hypertensive group than it was among normotensive subjects. To the best of our knowledge this is the first report suggesting that there is an association of the incidence of hypertension with an ENOS polymorphism located in the coding area of the gene. Larger studies are needed in order to confirm the implication of the ENOS 298 G in hypertension.
The result of our study is that we observed no association of aortic stiffness with the two studied polymorphisms of the ENOS. We can provide several explanations for this lack of an association of ENOS polymorphisms with arterial stiffness. One could suggest that the absence of differences in PWV among genotypes was due to the lack of effect of these polymorphisms on blood pressure. Although we cannot deny that blood pressure plays the determinant role in determining PWV, we and others have clearly shown that pressure-independent mechanisms can regulate large-artery stiffness [5, 19, 20] . Another explanation is that these polymorphisms do not influence the functioning of ENOS. This explanation is more probable for the ENOS G
IN23
T polymorphism because it is located in a non-coding area of this gene, which is consistent with the lack of an association with hypertension previously reported by Bonnardeaux et al. [16] . Although the functional role of the Glu 298 Asp has not yet been established, its localization in a coding area of the gene militates in favour of the hypothesis that it plays a functional role, especially insofar as differences between allele prevalences among normotensive and hypertensive subjects were observed. However, the heterogeneity of the ENOS could be due to some other gene variety, especially in the promoter region. Finally, ENOS could modulate arterial phenotypes other than PWV. Indeed, it is possible that ENOS gene is involved in flow-dependent dilatation of larger arteries, which is an NO-dependent phenomenon [21, 28] .
In conclusion, the present results do not suggest that two common polymorphisms of the ENOS gene are involved in the regulation of aortic stiffness both in hypertensive and in normotensive individuals. The higher prevalence of ENOS 298 G allele among hypertensives suggests that this gene is involved in essential hypertension but this observation needs further confirmation.
